Clinical Trial

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-17.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT07219407
Lead Sponsor Rapport Therapeutics Inc.
Conditions Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Enrollment 30 participants
Start Date 2025-12-15
Primary Completion 2028-02-03 (estimated)
Study Completion 2028-02-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-23